Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06337318 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06337318 · ClinicalTrials.gov record · last posted 2026-08-27

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

StatusRecruiting
PhasePhase 3
Started2024-10-23
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. It is not yet known if giving rituximab or mosunetuzumab works better in treating patients with follicular lymphoma with a low tumor burden.

Amendment record 239 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 239 times since 2024-03-27; most recent amendment 2026-07-23. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-08-13
Status change Not Yet Recruiting→Recruitingv3
Trial Details
NCT Number NCT06337318
Lead Sponsor National Cancer Institute (NCI)
Conditions Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features
Enrollment 600 participants
Start Date 2024-10-23
Primary Completion 2032-03-31 (estimated)
Study Completion 2032-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-27